TXG10x Genomics, Inc.

$80.64+518% 1Y

$80.64

$11.3452 weeks$97.82

TXG in its own filings

Nothing in TXG's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.

115

Events found in the filings · across 694 filings · the record starts in 2019

Hard flags: none
Hard flags
Most recent filing: Aug 7, 2026
Most recent filing · Form 10-Q
Record starts: Jun 6, 2019
Record starts · the earliest filing Ryufin holds for this name

Details›

Next results filingsame week as a year ago: expected around Nov 5, 2026
SEC comment-letter activity10 occurrences: 2020-09-08

SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.

What the company said

The company's own words from its current reports to the SEC, newest first

Aug 6, 202610x Genomics Reports Second Quarter 2026 Financial Results.Earnings release · press release
May 7, 202610x Genomics Reports First Quarter 2026 Financial Results.Earnings release · press release
Jan 12, 202610x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2025 Results.Earnings release · press release
Nov 14, 2025After more than eight years of exemplary service, on November 12, 2025 Eric S. Whitaker announced his intention to retire as Chief Legal Officer of 10x Genomics, Inc. (the “Company”) effective January 1, 2026.Director or officer change · Form 8-K
Nov 6, 202510x Genomics Reports Third Quarter 2025 Financial Results.Earnings release · press release